Jade Biosciences, Inc. (JBIO) Stock Price & Analysis
Jade Biosciences, Inc. (JBIO) rose 1.60% to USD 15.22 as of June 10, 2026 at 03:40 UTC, according to Nexqual real-time market data.
JBIO last closed at USD 14.98; the session ranged USD 14.28–15.37 on volume of 1,589,663 shares. Market capitalization is $926.29M, with a 52-week range of USD 6.57–28 (NCM). Source: Nexqual, June 10, 2026 at 03:40 UTC.
Key Statistics (as of June 10, 2026 at 03:40 UTC)
| Price | USD 15.22 |
|---|---|
| Change | ▲ 1.60% (up) |
| Previous Close | USD 14.98 |
| Open | USD 15.1 |
| Day Range | USD 14.28 – 15.37 |
| 52-Week Range | USD 6.57 – 28 |
| Volume | 1,589,663 shares |
| Market Cap | $926.29M |
| Exchange | NCM |
Technical Analysis (JBIO)
Nexqual's technical model rates JBIO "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24 (oversold) |
| vs SMA50 | Below (USD 21.14) |
| MACD | -1.72 (negative) |
Analyst Ratings (JBIO)
Wall Street analysts rate JBIO "Strong Buy" based on 7 analysts, with a mean price target of USD 49 (range USD 40–74), per Nexqual as of June 10, 2026 at 03:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 49 |
| High Target | USD 74 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (JBIO)
| Next Earnings Date | 2026-05-14 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.57 vs est -0.48 ▼ miss |
| 2025-09-30 | USD -0.48 vs est -0.67 ▲ beat |
| 2025-06-30 | USD -0.86 vs est -0.48 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financials & Fundamentals (JBIO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.29 |
| Current Ratio | 14.29 |
| Total Cash | $311.30M |
| Total Debt | $849,000 |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financial Health Score (JBIO)
Nexqual rates Jade Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $311M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$100M |
| Efficiency | Mixed — No data |
Ownership (JBIO)
| Insider Ownership | +0.93% |
|---|---|
| Institutional Ownership | +84.31% |
| Shares Outstanding | 60.86M |
| Float | 35.54M |
| Short % of Float | +8.38% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Leadership (JBIO)
Jade Biosciences, Inc. is led by Tom Frohlich (age 49), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:40 UTC.
| President, CEO & Director | Tom Frohlich (age 49) |
|---|---|
| CFO & Treasurer | Bradford D. Dahms (age 36) |
| President of Research & Development | Andrew James King BVMS, D.V.M. (age 45) |
| Senior Vice President of People | Lori Stewart |
| Senior Vice President of Finance | Jonathan Quick |
Major Backers & Investors (JBIO)
Notable institutional backers of Jade Biosciences, Inc. include FMR, LLC, Fidelity, Fairmount Funds Management LLC, according to Nexqual as of June 10, 2026 at 03:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.35% |
| Fidelity | 9.56% |
| Fairmount Funds Management LLC | 9.23% |
| RA Capital Management, L.P. | 7.44% |
| Bellevue Group AG | 7.09% |
| Venrock Adviser, LLC | 6.52% |
| Janus Henderson Group PLC | 6.29% |
| Baker Bros. Advisors, LP | 3.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.45% |
| BlackRock | 6.25% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
From Jade Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
- It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
- The company also develops JADE201 and JADE-003, which are in preclinical development stage.
- Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | USD 16.61 | ▲ 1.47% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.19 | ▲ 1.86% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:40 UTC. This page is informational and not investment advice.